Sleeve gastrectomy with jejunal bypass for the treatment of type 2 diabetes mellitus in patients with body mass index <35 kg/m2. A cohort study

Obesity Surgery

Volumn 22, Issue 7, 2012, Pages 1097-1103

  Alamo, Munir ^a,b   Sepúlveda, Matías ^a,b   Gellona, José ^c,d   Herrera, Mauricio ^e   Astorga, Cristián ^a   Manterola, Carlos ^f  

^a HOSPITAL DIPRECA   (Chile)

^b UNIVERSIDAD DIEGO PORTALES   (Chile)

^c Hospital El Pino   (Chile)

^d UNIVERSIDAD ANDRÉS BELLO   (Chile)

^e Hospital Regional de Osorno   (Chile)

^f UNIVERSIDAD DE LA FRONTERA   (Chile)

Author keywords

Bariatric surgery; Body mass index; Cohort studies; Jejunal bypass; Metabolic surgery; New technique; Obesity surgery; Sleeve gastrectomy; Type 2 diabetes mellitus

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; JEJUNOILEOSTOMY; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPERATION DURATION; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PYLORUS; REMISSION; SLEEVE GASTRECTOMY; SURGICAL ANATOMY; SURGICAL MORTALITY; TISSUE PRESERVATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHILE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GASTROPLASTY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; JEJUNUM; LAPAROSCOPY; MALE; MIDDLE AGED; OBESITY, MORBID; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84862605924     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0652-x     Document Type: Article

References (50)

1. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-52.
2. MacDonald Jr KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of noninsulin- dependent diabetes mellitus. J Gastrointest Surg. 1997;1(3):213-20 (discussion: 220).
3. Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes - a systematic review. Diabetes Metab Res Rev. 2004;20:438-45.
4. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-56.e5.
5. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-37.
6. Padwal RS. Review: bariatric surgery reduces weight and improves type 2 diabetes in adults. Evid Based Med. 2009;14(5):138.
7. Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010;20:776-90.
8. Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234-41.
9. DePaula A, Stival A, Halpern A, et al. Surgical treatment of morbid obesity: mid-term outcomes of the laparoscopic ileal interposition associated to a sleeve gastrectomy in 120 patients. Obes Surg. 2011;21(5):668-75.
10. Alamo M, Sepúlveda C, Zapata L. Vertical isolated gastroplasty with gastro-enteral bypass: preliminary results. Obes Surg. 2006;16(3):353-8.
11. de Menezes Ettinger JE, Azaro E, Mello CA, et al. Analysis of the vertical isolated gastroplasty: a new bariatric operation. Obes Surg. 2006;16(9):1261-3; author reply 1263-4.
12. Vandenbroucke JP, von Elm E, Altman DG, et al. STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163-94.
13. STROBE Statement. Strengthening the Reporting of Observational studies in Epidemiology. http://www.strobe-statement.org. Accessed 6 Apr 2011.
14. American Diabetes Association Position Statement. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62-9.
15. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Reviews/commentaries/ADA statements consensus statement. Diabetes Care. 2009;32:2133-5.
16. Robinson JD, Lupkiewicz SM, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40(6):1016-9.
17. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. Proc R Soc Lond Biol. 1902;69:352-3.
18. Elrick H, Stimmler L, Hlad Jr CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Invest. 1964;24:1076-82.
19. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49(Suppl 1):S16-29.
20. La Barre J. Sur les possibilités d'un traitement du diabetes par l'incrétine. Bull Acad R Med Belg. 1932;12:620-34.
21. Miller LJ, Malagelada JR, Taylor WF, et al. Intestinal control of human postprandial gastric function: the role of components of jejunoileal chyme in regulating gastric secretion and gastric emptying. Gastroenterology. 1981;80:763-9.
22. Layer P, Holst JJ, Grandt D, et al. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci. 1995;40:1074-82.
23. Bose M, Oliván B, Teixeira J, et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence? Obes Surg. 2009;19(2):217-29.
24. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14 Suppl 1:1-83.
25. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143-8.
26. Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21(6):738-43.
27. Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707-13.
28. Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenaljejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2: a report of two cases. Surg Obes Relat Dis. 2007;3:195-7.
29. DePaula AL, Macedo AL, Mota BR, et al. Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29. Surg Endosc. 2009;23(6):1313-20.
30. Tinoco A, El-Kadre L, Aquiar L, et al. Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg. 2011;35(10):2238-44.
31. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1-11.
32. Rubino F, Forgione A, Cummings D, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-9.
33. Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725-32.
34. Gersin KS, Keller JE, Stefanidis D, et al. Duodenal-jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14:275-8.
35. Rodriguez-Grunert L, Neto MPG, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal by-pass sleeve. Surg Obes Relat Dis. 2008;4:55-9.
36. Boza C, Muñoz R, Yung E, et al. Sleeve gastrectomy with ileal transposition (SGIT) induces a significant weight loss and diabetes improvement without exclusion of the proximal intestine. J Gastrointest Surg. 2011;15(6):928-34.
37. Cable CT, Colbert CY, Showalter T, et al. Prevalence of anemia after Roux-en-Y gastric bypass surgery: what is the right number? Surg Obes Relat Dis. 2011;7(2):134-9.
38. Simon SR, Zemel R, Betancourt S, et al. Hematologic complications of gastric bypass for morbid obesity. South Med J. 1989;82:1108-10.
39. Alvarez-Cordero R, Aragon-Viruette E. Post-operative complications in a series of gastric bypass patients. Obes Surg. 1992;2:87-9.
40. Halverson JD. Micronutrient deficiencies after gastric bypass for morbid obesity. Am Surg. 1986;52:594-8.
41. Loss AB, de Souza AA, Pitombo CA, et al. Analysis of the dumping syndrome on morbid obese patients submitted to Roux en Y gastric bypass. Rev Col Bras Cir. 2009;36(5):413-9.
42. Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-90.
43. Quigley E, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin N Am. 2010;24:943-59.
44. Greco M, De Micheli E, Lonardo A. Multifactorial hepatopathy in a patient with biliopancreatic diversion. Ann Ital Med Int. 2003;18(2):99-103. Italian.
45. Papadia F, Marinari GM, Camerini G, et al. Short-term liver function after biliopancreatic diversion. Obes Surg. 2003;13(5):752-5.
46. Riordan SM, McIver CJ, Williams R. Liver damage in human small intestinal bacterial overgrowth. Am J Gastroenterol. 1998;93(2):234-7.
47. Reinshagen K, Zahn K, Buch C, et al. The impact of longitudinal intestinal lengthening and tailoring on liver function in short bowel syndrome. Eur J Pediatr Surg. 2008;18(4):249-53.
48. Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol. 2006;12(26):4117-29.
49. Hartmann B, Thulesen J, Hansen BS, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47:370-6.
50. Santoro S, Milleo FQ, Malzoni CE. Enterohormonal changes alter digestive adaptation: five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg. 2008;18(1):17-26.